Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESFour years after the bill was first proposed by the Italian Parliament, the Italian Sunshine Act (Law 62/2022) was finally approved and officially published in the Official Gazette. The law entered into force June 26, 2022.
With the aim of fighting corruption and enhancing transparency in the healthcare sector, the new law will require life sciences companies to disclose relations with healthcare professional and organizations.
Any entity which, directly or in the role of intermediary, carries out an activity aimed at the production or marketing of medicines, medical devices, equipment, goods or services, including non-sanitary products, including nutritional products, in the field of human and animal health, at the organization of conferences and congresses concerning the same areas, will be subject to Law 62/2022.
Life sciences companies will report and disclose on a biannual basis via a central reporting platform, called Sanità Trasparente, all Transfers of Value (ToVs) – including monetary payments as well as in-kind, goods, services or other benefits – to individuals that exceed €100 per transaction, or €1000 annually. The TOV threshold for each HCO interaction is €1,000 per ToV or €2,500 annually. Manufacturers will also have to disclose all agreements that confer direct or indirect advantages to HCPs or HCOs, including congresses and other educational event participation, scientific committee and advisory board participation, research, consulting and speaking engagements (Art.3).
According to the approved law, licensing fees and ownership – via shares or bonds – shall likewise be disclosed on an annual basis (Art.4).
It is expected that the platform Sanità Trasparente will be developed and go live within six months of the Italian Sunshine Act entering into force of law. Whether the timeline is respected, the first period for which healthcare industry companies would be required to submit all disclosures would be from June 2023 through December 2023, with reporting due by June 2024 (for Art.3 reporting).
The information published on the platform Sanità Trasparente will be available for five years. Consent from the recipient will not be required, but it will be necessary to inform the individual on the modalities of data processing.
Failing to follow these rules could result in serious penalties: For either omissions or incomplete reporting of engagements, companies could face fines as high as 20 times the amount of the ToV in question, plus an additional sanction of €1,000 per infraction. For either omissions or incomplete reporting related to IP licensing fees and ownerships – via shares or bonds – companies could face fines of €5,000 to €50,000. Instances of false reporting would trigger fines starting at €5,000 and up to €100,000. The Ministry of Health is ultimately responsible for the monitoring and the enforcement of the law; the enforcement may be also done by the Tax Police in the context of standard tax audit.
IQVIA Commercial Compliance team is already working on the interpretation and preparation for disclosures according to the Italian Sunshine Act. From automating and managing the entire HCP/O contracting lifecycle; to capturing, collecting, and reporting global spend; to planning efficient and compliant HCP meetings and engagements – discover how our solutions can make compliance easier for you.
Partner with compliance experts to create, implement and manage efficient, end-to-end processes that ensure your organization is compliant with global engagement and transparency regulations and codes.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
